News
PXMD
0.7259
-3.51%
-0.0264
PAXMEDICA INC - EXPECTS TO TAKE IMMEDIATE ACTION IN RESPONSE TO AN URGENT REQUEST FOR IV SURAMIN FROM MOH OF MALAWI
Reuters · 2h ago
PAXMEDICA RESPONDS TO EMERGENCY REQUEST FOR IV SURAMIN AND COMMITS TO PROVIDE IMMEDIATE ACCESS TO PAX-101
Reuters · 2h ago
PAXMEDICA INC - EXPECTS TO TAKE IMMEDIATE ACTION IN RESPONSE TO AN URGENT REQUEST FOR IV SURAMIN FROM MINISTRY OF HEALTH (MOH) OF MALAWI
Reuters · 2h ago
Weekly Report: what happened at PXMD last week (0415-0419)?
Weekly Report · 1d ago
12 Health Care Stocks Moving In Friday's Pre-Market Session
Chromocell Therapeutics (AMEX:CHRO) stock increased by 21.6% to $1.49 during Friday's pre-market session. Kineta stock moved upwards by 16.62% and Erasca stock rose 13.73%. Nexalin Technology (NASDAQ:NXL) stock fell 18.4% during the day.
Benzinga · 4d ago
PAXMEDICA SHARES UP 6% PREMARKET ON MALAWI'S REQUEST FOR ACCESS TO SLEEPING SICKNESS DRUG
Reuters · 6d ago
BUZZ-PaxMedica rises on Malawi's request for access to sleeping sickness drug
PaxMedica's PXMD.O shares rise 9.1% to 72 cents in extended trading. Malawi health ministry's urgent request for access to IV suramin used to treat sleeping sickness. Company will file marketing application for drug with U.S. FDA.
Reuters · 6d ago
PAXMEDICA: RESPONDING TO MALAWI MINISTRY OF HEALTH'S REQUEST, IN CONTACT WITH REGULATORY AUTHORITIES IN U.S., MALAWI TO HELP WITH EMERGENCY
Reuters · 6d ago
12 Health Care Stocks Moving In Tuesday's Intraday Session
Palisade Bio (NASDAQ:PALI) stock increased by 65.1% to $6.87 during Tuesday's regular session. China SXT Pharmaceuticals and Intra-Cellular Therapies were among the gainers. Calidi Biotherapeutics (AMEX:CLDI) shares decreased by 58.5% during the session.
Benzinga · 6d ago
Dow Jumps Over 300 Points; Goldman Sachs Posts Upbeat Earnings
The Dow Jones index gained more than 300 points on Monday. Goldman Sachs Group Inc. Reported better-than-expected first-quarter earnings. The Dow traded up 0.89% to 38,321.05 while the NASDAQ rose 0.70%. Soligenix, Inc. Shares shot up 98% after being granted orphan drug designation for MarVax.
Benzinga · 04/15 14:00
12 Health Care Stocks Moving In Monday's Pre-Market Session
Soligenix (NASDAQ:SNGX) stock increased by 95.1% to $0.75 during Monday's pre-market session. The company's market cap stands at $7.9 million. Cartesian Therapeutics and Longeveron also moved upwards. Losers Marinus Pharma and PaxMedica stock decreased by more than 20%.
Benzinga · 04/15 12:07
Weekly Report: what happened at PXMD last week (0408-0412)?
Weekly Report · 04/15 11:41
12 Health Care Stocks Moving In Friday's After-Market Session
Qilian Intl Hldg Gr (NASDAQ:QLI) stock moved upwards by 50.4% to $1.14 during Friday's after-market session. Allarity Therapeutics stock rose 18.09% and Galecto stock increased by 5.58%. PaxMedica stock declined by 8.0% during the session.
Benzinga · 04/12 20:31
Nasdaq Down 300 Points; BlackRock Posts Upbeat Earnings
The Dow Jones index fell more than 500 points on Friday. BlackRock, Inc. Posted stronger-than-expected earnings for first quarter. PaxMedica shares shot up 106% on Friday after company announced a deal to sell robots. Asian markets closed mostly lower in Asia Pacific markets.
Benzinga · 04/12 19:00
Why JPMorgan Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Friday's Mid-Day Session
JPMorgan Chase & Co. Shares dipped 5.1% to $185.49 following first-quarter earnings on Friday. PaxMedica, Inc. Shares jumped 143% after the company reported better-than-expected results on Thursday. Rent the Runway shares jumped 162% on Thursday after reporting mixed results.
Benzinga · 04/12 18:47
PaxMedica Shares Surge on Manufacturing Milestone for Lead Candidate PAX-101
PaxMedica shares more than doubled Friday after company achieves key manufacturing milestone for lead drug candidate. Shares were at 84 cents in recent trading after closing at 41 cents Thursday. PaxMedica is pursuing approval for a drug for sleeping sickness. The drug is also being evaluated for autism spectrum disorder.
Dow Jones · 04/12 18:17
12 Health Care Stocks Moving In Friday's Intraday Session
PaxMedica stock increased by 110.9% to $0.87 during Friday's regular session. Q32 Bio (NASDAQ:QTTB) shares rose 23.89% during the session. Cyclacel Pharmaceuticals shares increased by 20.45%. SenesTech and Motus GI Hldgs were among the losers.
Benzinga · 04/12 16:31
Gold Jumps Over 2%; Wells Fargo Earnings Top Views
U.S. Stocks traded lower midway through trading on Friday. The Dow traded down 0.82% while the Nasdaq Composite fell more than 1%. Wells Fargo & Company posted stronger-than-expected earnings for first quarter. Energy shares rose by 0.9% on Friday; energy shares rose in Asian markets.
Benzinga · 04/12 16:06
Penny Stock PaxMedica's African Sleeping Sickness Candidate Moves Closer To FDA Marketing Application Submission, Stock Rallies
PaxMedica completed the execution of three pivotal registration/validation batches of suramin. PaxMedica's PAX-101, an IV formulation of suramine, is the first and only form to be approved for Human African Trypanosomiasis. The company plans to submit a New Drug Application to the FDA in Q4 2024.
Benzinga · 04/12 16:02
Dow Dips 200 Points; Citigroup Posts Upbeat Earnings
U.S. Stocks traded lower on Friday, with the Dow Jones index falling around 200 points. Citigroup posted better-than-expected earnings for its first quarter. Energy shares rose by 1.1% on Friday. PaxMedica, Inc. Shares shot up 137% after the company reported better than expected results. Asian markets closed mostly lower in trading on Friday; European shares mostly higher.
Benzinga · 04/12 13:49
More
Webull provides a variety of real-time PXMD stock news. You can receive the latest news about PaxMedica, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About PXMD
PaxMedica, Inc. is a clinical-stage biopharmaceutical company. The Company is focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to neurodegenerative disorders, such as Fragile X Tremor Ataxia Syndrome (FXTAS) and post-viral Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating physical and cognitive disorder believed to be viral in origin and with rising incidence globally due to the long-term effects of SARS-CoV-2 (COVID-19). Its lead program PAX-101 is an intravenous formulation of suramin, in the treatment of ASD and the advancement of the clinical understanding of using that agent against other disorders fragile X syndrome (FXS), FXTAS, ME/CFS and Long COVID-19 Syndrome (LCS), a clinical diagnosis in individuals who have been previously infected with COVID-19.